－S 622 －
― F-115 ―
Dilated cardiomyopathy and aortic dissection in a Mosaic Turner syndrome with male phenotype
안동병원, 심혈관 내과
*이은규, 김건영, 현대우
We report a case of dilated cardiomyopathy in a patient with 46,X,del(Y)/45,X karyotype, mosaic Turner syndrome. A 45-year-old male was admitted to the hospital because of dyspnea. On physical examination, he was found to be short stature and sexual infantism. Echocardiography revealed severe left ventricular systolic dysfunction, all chamber dilatation, bicuspid aortic valve, annuloaortic ectasia and aortic dissection.
Chromosomal study revealed 46,X,del(Y)(q11.23)/45,X. An emphasis is put on the need of thorough examination of cardiovascular system, specialized on congenital heart disease including aortic dilatation with the risk of dissection, and early development of ischemic heart disease.
Regular monitering as well as adequate therapy in patients suffering from this genetically determined disorder is recommended
― F-116 ―
Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease
전남대학교병원심장센터1, 경희대학교병원심장센터2, 전남대학교공과대학3
*김성수
1, 홍영준
1, 정명호
1, 김 원
2, 김현국
1, 고점석
1, 이민구
1, 심두선
1, 박근호
1, 윤남식
1, 윤현주
1김계훈
1, 박형욱
1, 김주한
1, 안영근
1, 조정관
1, 박종춘
1, 김 훈
3, 조동련
3, 강정채
1Background: Despite abciximab (ReoPro®)-coated stent has inhibitory effect on coronary artery restenosis, long term clinical outcome is unknown. Methods: This study was a prospective, randomized trial to compare the effects of abciximab-coated stent, which was implanted for 95 patients, with those of control stent, which was implanted for 93 patients for de novo coronary lesions. We evaluated the major adverse cardiac events (MACE) at two-year follow-up. Results: Although there were no significant differences in the incidences of cardiac death (0%
vs. 1.1%, p=0.3) and target vessel revascularization (16% vs. 21%, p=0.4) between both groups, there was a trends toward lower incidences of non-fatal myocardial infarction (0% vs. 2.3%, p=0.16) and total MACE (16% vs. 24%, p=0.19) in abciximab-coated stent group compared with control stent group. Moreover, stent thrombosis did not occur in abciximab-coated stent group. Six month intravascular ultrasound analysis showed that an increase of neointimal hyperplasia area was significantly smaller in abciximab-coated stent group compared with control stent group (2.0±1.6 mm2 vs. 3.4±1.7 mm2, p=0.001). Conclusions: There is a trend that abciximab-coated stents inhibit neointimal hyperplasia and had lower total MACE and no stent thrombosis at two-year follow-up.
